| 1 |
33468383 | Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen. | 2021 May |
3 |
| 2 |
34330763 | Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. | 2021 Jul |
2 |
| 3 |
32062671 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. | 2020 Feb 16 |
2 |
| 4 |
32163218 | Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo. | 2020 May |
2 |
| 5 |
32271417 | Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy. | 2020 Mar |
1 |
| 6 |
32444490 | Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. | 2020 Jun 9 |
1 |
| 7 |
33120790 | Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. | 2020 Oct 23 |
1 |
| 8 |
30307354 | Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. | 2019 |
1 |
| 9 |
30422156 | Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. | 2019 Jan 1 |
1 |
| 10 |
30739089 | A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. | 2019 Feb 9 |
1 |
| 11 |
30792807 | Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status. | 2019 |
1 |
| 12 |
28229371 | Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records. | 2018 Sep |
1 |
| 13 |
28040715 | Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. | 2017 Jan |
1 |
| 14 |
28418176 | Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer. | 2017 Jul |
1 |
| 15 |
26515332 | KRAS polymorphisms are associated with survival of CRC in Chinese population. | 2016 Apr |
1 |
| 16 |
27143148 | Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. | 2016 Jun |
1 |
| 17 |
27155924 | [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer]. | 2016 Jun |
1 |
| 18 |
27229742 | A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study). | 2016 |
1 |
| 19 |
28101205 | Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. | 2016 Dec |
1 |
| 20 |
28356789 | Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. | 2016 |
1 |
| 21 |
24889488 | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. | 2015 Jan |
1 |
| 22 |
25553091 | ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. | 2015 |
3 |
| 23 |
25870609 | Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. | 2015 |
2 |
| 24 |
25937522 | FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. | 2015 Jul |
1 |
| 25 |
25998052 | Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. | 2015 Jul 28 |
1 |
| 26 |
26525741 | High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment. | 2015 Nov 2 |
2 |
| 27 |
23821376 | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. | 2014 Jun |
2 |
| 28 |
24468885 | Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. | 2014 Jun |
1 |
| 29 |
24505265 | Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. | 2014 |
8 |
| 30 |
24764664 | Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. | 2014 Apr 21 |
2 |
| 31 |
24772300 | KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. | 2014 May |
1 |
| 32 |
24960403 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. | 2014 Jul 29 |
2 |
| 33 |
25818736 | A meta analysis of cetuximab plus oxaliplatin based chemotherapy regimen for metastatic colorectal cancer. | 2014 Mar |
2 |
| 34 |
23175150 | KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. | 2013 Jan 15 |
3 |
| 35 |
23689915 | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. | 2013 Jul |
1 |
| 36 |
23730417 | Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. | 2013 Jun |
6 |
| 37 |
23822592 | Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. | 2013 Oct |
2 |
| 38 |
22740893 | Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation. | 2012 Feb |
1 |
| 39 |
22876876 | Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. | 2012 Aug 9 |
3 |
| 40 |
22909976 | K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. | 2012 Nov |
3 |
| 41 |
22948721 | Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. | 2012 |
1 |
| 42 |
23209813 | KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. | 2012 |
6 |
| 43 |
23226426 | No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. | 2012 |
1 |
| 44 |
23268018 | [Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment]. | 2012 Nov |
2 |
| 45 |
20972872 | Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. | 2011 Aug |
1 |
| 46 |
21228335 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. | 2011 Jul |
2 |
| 47 |
21508389 | Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. | 2011 Apr |
2 |
| 48 |
21635994 | Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. | 2011 Apr |
1 |
| 49 |
21894049 | KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. | 2011 |
1 |
| 50 |
20354524 | Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. | 2010 Apr 13 |
3 |